胃癌市场：KOL 洞察

本报告调查全球胃癌市场，提供了有关胃癌的市场概况和信息，从Herceptin和trastuzumab生物仿製药在一线治疗中的作用演变，到Enhertu 在二线治疗中的广阔潜力，深入挖掘最新进展。一线的 KOL 对目前的治疗方法和新选择进行了全面分析，强调了主要挑战和未来机会。

目录

执行摘要

目前与未来的治疗演算法

研究目的

上市治疗

• 化疗方案、当前治疗趋势、挑战和未满足的需求
  • Herceptin (trastuzumab; Roche)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
  • Cyramza (ramucirumab; Lilly)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)

后期管道计划

• 免疫治疗
  • Durvalumab (Imfinzi; AstraZeneca)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Atezolizumab (Tecentriq; Roche)
• 标靶生物治疗
  • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
  • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte
  • Bemarituzumab (Five Prime Therapeutics/Amgen)
  • Zanidatamab (ZW25; Zymeworks)
  • Evorpacept (ALX Oncology)
  • Catumaxomab (Removab; LintonPharm)
  • ARX788 (Ambrx/Zhejiang Medicine)
• 标靶口服治疗
  • Stivarga (regorafenib; Bayer)
• 下一代治疗
  • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

未来治疗趋势

• 细胞疗法与胃癌疫苗
  • 胃癌治疗中其他有前景的技术

附录

新闻

From the evolving role of Herceptin and trastuzumab biosimilars in first-line therapy to the promising potential of Enhertu in second-line treatment, this report delves into the latest advancements in gastric cancer therapies. Leading KOLs provide a thorough analysis of current treatments and emerging options, highlighting key challenges and future opportunities. Discover how these insights are set to transform the gastric cancer treatment landscape.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed treatments

• Chemotherapy regimens, current treatment trends, challenges and unmet needs
  • Herceptin (trastuzumab; Roche)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
  • Cyramza (ramucirumab; Lilly)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)

Late-stage pipeline programmes (120)

• Immunotherapies
  • Durvalumab (Imfinzi; AstraZeneca)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Atezolizumab (Tecentriq; Roche)
• Targeted biologic therapies
  • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
  • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
  • Bemarituzumab (Five Prime Therapeutics/Amgen)
  • Zanidatamab (ZW25; Zymeworks)
  • Evorpacept (ALX Oncology)
  • Catumaxomab (Removab; LintonPharm)
  • ARX788 (Ambrx/Zhejiang Medicine)
• Targeted oral therapies
  • Stivarga (regorafenib; Bayer)
• Next-generation therapies
  • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

Future treatment trends

• Cell therapies and gastric cancer vaccines
  • Other promising technologies in the pipeline for gastric cancer

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

News